Literature DB >> 28538249

Norovirus and Clostridium difficile outbreaks: squelching the wildfire.

Ann Fisher1, Louise M Dembry.   

Abstract

PURPOSE OF REVIEW: Gastrointestinal outbreaks in the healthcare setting cause increased morbidity and mortality in an already vulnerable population. Optimization of infection prevention measures can be a challenge in healthcare settings. This review describes new literature that may change the traditional infection prevention approach to such outbreaks. RECENT
FINDINGS: Asymptomatic carriers of both norovirus and Clostridium difficile can pose risk of transmission to others and the environment. Rapid recognition and diagnosis can decrease the extent of an outbreak. No-touch technologies for environmental disinfection are new and effective tools. Infection prevention consultant services and systems redesign can augment efforts to control baseline infection rates and outbreaks. Antimicrobial stewardship continues to be essential to prevent C. difficile infection.
SUMMARY: New approaches are needed to stem the tide of norovirus and C. difficile clusters and outbreaks in healthcare settings. Accurate recognition, testing, and implementation of infection prevention measures can be supported with rapid testing modalities, access to updated guidelines and no-touch disinfection systems. The work-environment culture should be carefully assessed and restructured using human engineering models to promote effective infection prevention practices. Antimicrobial stewardship initiatives are needed at the bedside and at national levels.

Entities:  

Mesh:

Year:  2017        PMID: 28538249     DOI: 10.1097/QCO.0000000000000382

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  1 in total

Review 1.  Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools.

Authors:  Zachary A Rubin; Elise M Martin; Paul Allyn
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.